Trevi

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Retrieved on: 
Tuesday, April 2, 2024
Science, Teva Pharmaceuticals, GSK, Executive, Inflammation, Patient, Knowledge, MD, Cough, Drug, Trevi, IPF, Idiopathic pulmonary fibrosis, Medical school, RCC, Therapy, Chronic cough, Pharmaceutical industry

NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.

Key Points: 
  • Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical development at Bellus Health.
  • Her background spans various stages of the clinical development process including both strategic and executional roles, as well as the science of cough.
  • "I am happy to welcome Meg to our team," said David Clark, Chief Medical Officer of Trevi Therapeutics.
  • I am thrilled to have the ability to continue my work in chronic cough by joining the Trevi team to further the development of Haduvio for these patients."

Nippon Shokubai’s Newly Developed Material Contributed the Successful Demonstration of Groundbreaking Renewable Seawater Desalination Plant in Hawaii

Retrieved on: 
Thursday, February 29, 2024
Environment, Other Energy, Chemicals, Plastics, Manufacturing, Sustainability, Green Technology, Energy, Other Natural Resources, Natural Resources, Acquisition, Comparison, Multimedia, Chemistry, Sodium chloride, Data collection, Polymer, Trevi, Osmosis, Drinking water, Ethylene oxide, Assembly of Dust, Electronics, Capital, Recycling, Salt, Seawater, Water, Fresh water, NELHA, Sewage treatment

The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities.

Key Points: 
  • The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities.
  • Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).
  • This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).
  • About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers.

Marlowe Ridgeview Offers Spa-Like Lifestyle with Convenient Location

Retrieved on: 
Wednesday, February 21, 2024
Walt Disney World, FedEx, Aldi, Trevi, Relaxation, Publix, Walmart, UPS, Ford, HCA Healthcare, Restaurant, Target

"We're excited to bring Marlowe Ridgeview to Davenport.

Key Points: 
  • "We're excited to bring Marlowe Ridgeview to Davenport.
  • Marlowe Ridgeview residences come in one-, two- and three-bedroom layouts that range from 807 to 1,261 sq.
  • Marlowe Ridgeview is in a prime location with grocery stores like Publix and Aldi, as well as big box stores including Target and Walmart close by.
  • Marlowe Ridgeview is targeting a mid-2024 opening date with final completion slated for late 2024.

Helping A Hero, Bass Pro Shops and Lennar Welcome Wounded Veteran, Retired US, Corporal Corey Dingman, to His New Adaptive Lennar Home in Pensacola, FL

Retrieved on: 
Monday, January 22, 2024
Elbow, Bass, Trevi, Family, Leg, Bass Pro Shops, Injury, Frustration, Ashley Furniture Industries, Terror, Veteran, Love, Corporal, Pain, Traumatic brain injury, Burns, Military personnel, Hearing, IED, Army Wounded Warrior Program, Army

PENSACOLA, Fla., Jan. 22, 2024 /PRNewswire/ -- Helping a Hero, a non-profit providing support for military personnel severely injured in the war on terror, Bass Pro Shops and Lennar, one of the nation's leading homebuilders, recently held a Ceremony to Welcome Retired US, Corporal Corey Dingman, to his new adapted Lennar home. Corporal Dingman and his family were greeted by special guests from Helping a Hero, including Founder, Meredith Iler, Staff Sergeant Daniel Gilyeat as well as Jeff Bergosh Escambia County District 1 Commissioner and Lennar Regional Vice President, Matt Devereaux, Lennar Gulf Coast Division President, Angela Wisdom and Lennar Associates. The new adapted home is part of Lennar's Saddle Ridge community located in the Beulah area of Pensacola, Florida which is in close proximity to the NAS Naval Base.

Key Points: 
  • This Welcome Home Ceremony is part of the Helping a Hero 100 Homes Challenge, which was launched by Johnny Morris, Founder and CEO of Bass Pro Shops.
  • Lennar has joined the effort and has completed 6 homes and is in progress on 8 more for wounded veterans through Helping a Hero.
  • The home features wider doors and hallways which provide the ability for Corporal Dingman to move more easily inside the home.
  • It's an honor for Helping a Hero, Bass Pro Shops and Lennar to come together to provide an adapted home to Corporal Dingman and his family."

Trevi Therapeutics Provides Business Updates

Retrieved on: 
Thursday, January 4, 2024
Conference, Clutch (eggs), Idiopathic pulmonary fibrosis, IPF, Brain, Therapy, RCC, Trevi, Patient, Chronic cough, Pharmaceutical industry

NEW HAVEN, Conn., Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates.

Key Points: 
  • NEW HAVEN, Conn., Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates.
  • Management will be attending the 13th Annual LifeSci Partners Corporate Access Event in San Francisco from January 8-10 and will be available to discuss updates.
  • This event takes place during the week of the annual J.P. Morgan Health Care Conference.
  • "Our team is very excited about Trevi's outlook for 2024 having initiated two clinical trials in chronic cough and the Human Abuse Potential study late in 2023," said Jennifer Good, President and CEO of Trevi Therapeutics.

Helping A Hero, Bass Pro Shops and Lennar Break Ground on Home for Wounded Veteran, Corporal Corey Dingman, USA (Ret.), in Pensacola, FL

Retrieved on: 
Friday, October 13, 2023
Army, Elbow, Family, Trevi, Formula E Race at Home Challenge, Hero, Hearing, Injury, Corporal, Safety, Medivac (TV series), Terror, Traumatic brain injury, Military personnel, Leg, A Hero, Bass, Army Wounded Warrior Program, IED, Burns, Bass Pro Shops, Dingman, The Global War on Terrorism Memorial Foundation, Nightclub, Lennar

PENSACOLA, Fla., Oct. 13, 2023 /PRNewswire/ -- Helping a Hero, a non-profit providing support for military personnel severely injured in the war on terror, Bass Pro Shops and Lennar, one of the nation's leading homebuilders, today broke ground on a Lennar home for Corporal Corey Dingman USA (Ret.). Corporal Dingman and his family were greeted by special guests from Helping a Hero, including Founder, Meredith Iler, retired Marine Staff Sergeant Daniel Gilyeat, as well as Lennar Southeast Regional Vice President, Matt Devereaux and Lennar Associates. The new adapted home is part of Lennar's Saddle Ridge community located in the Beulah area of Pensacola, Florida.

Key Points: 
  • The groundbreaking is part of Helping a Hero's 100 Homes Challenge, which was launched by Johnny Morris, Founder and CEO of Bass Pro Shops.
  • Lennar has joined the effort and committed to building 10 homes for Helping a Hero as part of the 100 Homes Challenge.
  • "It is an honor to partner with Lennar and Bass Pro Shops to build this adapted home for Corporal Corey Dingman.
  • "We hope this home provides Corporal Dingman and his family a happy place to enjoy life and make family memories."

Trevi Therapeutics to Participate in Upcoming June Conferences

Retrieved on: 
Tuesday, May 30, 2023
University of Southern California, Critical Care Medicine (journal), Trevi, Keck School of Medicine of USC, Chronic cough, MD, Patient, Division, Prurigo nodularis, IPF, Therapy, Conference, Idiopathic pulmonary fibrosis, Pharmaceutical industry, HAVEN, Medicine

NEW HAVEN, Conn., May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following conferences in June. In addition, Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will be presenting data from Trevi's Phase 2 CANAL trial in IPF chronic cough at the American Cough Conference on June 9th.

Key Points: 
  • NEW HAVEN, Conn., May 30, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following conferences in June.
  • In addition, Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, will be presenting data from Trevi's Phase 2 CANAL trial in IPF chronic cough at the American Cough Conference on June 9th.
  • Presenters: Jennifer Good, President and CEO of Trevi Therapeutics, Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, and Peter Dicpinigaitis, MD, Professor of Medicine, Albert Einstein College of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, Director, Montefiore Cough Center and Editor-in-Chief, LUNG
    Registration: Investors and analysts can register to attend the in-person event by using the following link: https://ventures.yale.edu/yale-innovation-summit
    Presenter: Toby Maher, MD, Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California

Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023

Retrieved on: 
Tuesday, May 9, 2023
Montefiore Medical Center, Q&A, Critical Care Medicine (journal), Trevi, Yale school, Yale School of Management, EDT, Cough, Chronic cough, MD, Patient, Division, Management, Prurigo nodularis, Therapy, IPF, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Medicine

NEW HAVEN, Conn., May 9, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced its participation at the upcoming Yale Innovation Summit taking place from May 31 – June 1 at the Yale School of Management. The Company will present on its differentiated central and peripheral mechanism in cough and the potential broad translatability across cough indications. 

Key Points: 
  • The Company will present on its differentiated central and peripheral mechanism in cough and the potential broad translatability across cough indications.
  • Trevi's executives will be joined by one of the thought leaders in cough, Peter Dicpinigaitis, MD.
  • Dr. Dicpinigaitis will discuss the various central and peripheral pathways in cough and why a centrally active mechanism is generating such interest.
  • Trevi will also share insights on the patient and commercial potential of Haduvio with additional details from its physician and payer market research across chronic cough indications.

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, March 8, 2023
Orange Book, Chronic cough, Nalbuphine, Patent, Trevi, IPF, United States Patent and Trademark Office, Idiopathic pulmonary fibrosis, Therapy, Pharmaceutical industry, HAVEN

(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.

Key Points: 
  • (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.
  • Trevi expects the resulting patent will be Orange Book-listable with an anticipated expiration in 2039.
  • Trevi intends to continue to prosecute additional patent applications to further enhance its existing patent estate protecting nalbuphine ER across multiple chronic cough conditions as additional clinical data is generated.
  • "We are pleased with this allowance of claims to further secure IP protection for Haduvio through 2039 for the treatment of chronic cough in IPF," said Jennifer Good, President and CEO of Trevi Therapeutics.

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

Retrieved on: 
Monday, December 19, 2022
United, Prurigo nodularis, Route of administration, Nalbuphine, Interstitial lung disease, Trevi, Partnership, Itch, Risk, Conference, Chronic cough, Vicki Belo, Safety, DEA, IPF, Therapy, Idiopathic pulmonary fibrosis, Cough, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 19, 2022  /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following investor and partnership conferences in January. These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.

Key Points: 
  • These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.
  • Biotech Showcase 2023 (January 9-11, 2023)
    For more information or to register, please click here .
  • Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
  • The ĸ- and µ-opioid receptors are centrally and peripherally active and known to be critical mediators of cough and itch.